Our data support further investigations developing the miRNA (miR-125a/miR-205) cluster as a novel, effective HER3-targeted therapy to enhance the efficacy of trastuzumab and paclitaxel against HER2-overexpressing breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.